FDA Approves New Weight Loss Drug, Zepbound, Expected to Hit Shelves After Thanksgiving
Guam News Factor- The US Food and Drug Administration (FDA) has recently given its seal of approval for a new weight loss medication called Zepbound. Expected to be available shortly after Thanksgiving, Zepbound belongs to a new class of medications known as GLP-1 agonists, which have been gaining popularity over the years.
Similar to other GLP-1 agonists like Ozempic and Wegovy from Novo Nordisk, as well as Eli Lilly’s Mounjaro, Zepbound is targeted towards individuals without diabetes but who are at risk of complications due to excess weight. Ozempic and Mounjaro are generally prescribed to individuals with diabetes to help regulate blood sugar levels.
Clinical trials have shown that Zepbound can lead to an average weight loss of 52 pounds, a result comparable to that of bariatric surgery. The main ingredient in Zepbound, tirzepatide, mimics a hormone that reduces food cravings and imitates another hormone to improve the breakdown of sugar and fat in the body.
Zepbound is approved for use in adults with a body mass index (BMI) of at least 30 or a BMI of 27 or more with an additional weight-related condition. However, the drug should be used in conjunction with a reduced-calorie diet and exercise routine to maximize its effectiveness.
One potential hurdle for individuals interested in trying Zepbound is its price. With a cost of approximately $1,060 for a month’s supply, the drug may pose affordability issues for many eligible individuals. However, further developments are expected to occur, possibly leading to a decrease in its cost.
Like most medications, Zepbound does come with a list of potential side effects. These include nausea, diarrhea, vomiting, constipation, stomach pain, hair loss, belching, and reflux. Pregnant individuals should avoid taking Zepbound, and patients should be carefully monitored for signs of depression or suicidal thoughts.
Zepbound is set to hit the US market after Thanksgiving, and a steady increase in supply is anticipated throughout 2024. As the holiday season approaches, many individuals may start considering this new weight loss medication as a potential solution to their health goals. However, it is important to consult with a healthcare professional before starting any new medication or weight loss regimen.